CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 million EC and U.S. FDA label updates for CARVYKTI ® to include overall survival benefit versus standard of care ...
Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- ...
© 2005-2025 CBS INTERACTIVE ALL RIGHTS RESERVED. CBS Sports is a registered trademark of CBS Broadcasting Inc. 247Sports is a registered service mark of CBT Sports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results